Citius Oncology Plans Stock Offering; Shares Down

MT Newswires Live

2025/07/14

Citius Oncology (CTOR) filed a registration statement Monday for the potential sale of up to $15 million of common shares, and accompanying warrants to buy up to $15 million common shares.

The number of securities and per-share prices were not specified in the filing.

The company said it plans to use the net proceeds to commercialize Lymphir, including milestone, royalty or other payments it has to make under current license deals, and for working capital and general corporate purposes.

The company added that if the offering generates at least $10 million of gross proceeds, it must fully repay the roughly $3.8 million principal due under the August 2024 promissory note issued to Citius Pharmaceuticals (CTXR).

Shares of Citius Oncology fell more than 14% and Citius Pharmaceuticals rose over 4% in recent trading.

Price: 2.53, Change: -0.29, Percent Change: -10.28

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2551182891"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551182891\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551182891?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-14 22:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551182891","market":"sh","top_or_hot":-1,"title":"Citius Oncology Plans Stock Offering; Shares Down","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> (CTOR) filed a registration statement Monday for the potential sale of up to $15 million of common shares, and accompanying warrants to buy up to $15 million common shares.</p><p>The number of securities and per-share prices were not specified in the filing.</p><p>The company said it plans to use the net proceeds to commercialize Lymphir, including milestone, royalty or other payments it has to make under current license deals, and for working capital and general corporate purposes.</p><p>The company added that if the offering generates at least $10 million of gross proceeds, it must fully repay the roughly $3.8 million principal due under the August 2024 promissory note issued to Citius Pharmaceuticals (CTXR).</p><p>Shares of Citius Oncology fell more than 14% and Citius Pharmaceuticals rose over 4% in recent trading.</p><p>Price: 2.53, Change: -0.29, Percent Change: -10.28</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citius Oncology Plans Stock Offering; Shares Down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCitius Oncology Plans Stock Offering; Shares Down\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-07-14 22:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> (CTOR) filed a registration statement Monday for the potential sale of up to $15 million of common shares, and accompanying warrants to buy up to $15 million common shares.</p><p>The number of securities and per-share prices were not specified in the filing.</p><p>The company said it plans to use the net proceeds to commercialize Lymphir, including milestone, royalty or other payments it has to make under current license deals, and for working capital and general corporate purposes.</p><p>The company added that if the offering generates at least $10 million of gross proceeds, it must fully repay the roughly $3.8 million principal due under the August 2024 promissory note issued to Citius Pharmaceuticals (CTXR).</p><p>Shares of Citius Oncology fell more than 14% and Citius Pharmaceuticals rose over 4% in recent trading.</p><p>Price: 2.53, Change: -0.29, Percent Change: -10.28</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTXR","symbol_name":"Citius Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2551182891","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551182891","pubTimestamp":1752502296,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Citius Oncology  filed a registration statement Monday for the potential sale of up to $15 million of common shares, and accompanying warrants to buy up to $15 million common shares.The number of securities and per-share prices were not specified in the filing.The company said it plans to use the net proceeds to commercialize Lymphir, including milestone, royalty or other payments it has to make under current license deals, and for working capital and general corporate purposes.The company added that if the offering generates at least $10 million of gross proceeds, it must fully repay the roughly $3.8 million principal due under the August 2024 promissory note issued to Citius Pharmaceuticals .Shares of Citius Oncology fell more than 14% and Citius Pharmaceuticals rose over 4% in recent trading.Price: 2.53, Change: -0.29, Percent Change: -10.28","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTXR":"Citius Pharmaceuticals, Inc.","BK4139":"生物科技","CTOR":"CITIUS ONCOLOGY INC","BK4007":"制药"},"translate_title":"Citius Oncology计划发行股票；股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTOR":0.9,"CTXR":0.9},"content_text":"Citius Oncology (CTOR) filed a registration statement Monday for the potential sale of up to $15 million of common shares, and accompanying warrants to buy up to $15 million common shares.The number of securities and per-share prices were not specified in the filing.The company said it plans to use the net proceeds to commercialize Lymphir, including milestone, royalty or other payments it has to make under current license deals, and for working capital and general corporate purposes.The company added that if the offering generates at least $10 million of gross proceeds, it must fully repay the roughly $3.8 million principal due under the August 2024 promissory note issued to Citius Pharmaceuticals (CTXR).Shares of Citius Oncology fell more than 14% and Citius Pharmaceuticals rose over 4% in recent trading.Price: 2.53, Change: -0.29, Percent Change: -10.28","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}